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Abstract
Background. Disease and treatment contribute to cognitive late effects following pediatric low-grade glioma (LGG). 
We analyzed prospectively collected neuropsychological data of German pediatric LGG survivors and focused on 
the impact of hydrocephalus at diagnosis, neurofibromatosis type 1 (NF1) status, and extent of surgery.
Methods. We used the Neuropsychological Basic Diagnostic screening tool based on the Cattell–Horn–Carroll 
model for intelligence and the concept of cross-battery assessment at 2 and 5 years from diagnosis for 316 pa-
tients from the German pediatric LGG study and LGG registry (7.1 years median age; 45 NF1; cerebral hemispheres 
16%, supratentorial midline 39%, infratentorial 45%). Hydrocephalus was classified radiologically in 137 non-NF1 
patients with infratentorial tumors (95/137 complete/subtotal resection).
Results. Patients with NF1 versus non-NF1 exhibited inferior verbal short-term memory and visual processing 
(P < .001–.021). In non-NF1 patients, infratentorial tumor site and complete/subtotal resection were associated 
with sequelae in visual processing, psychomotor speed, and processing speed (P < .001–.008). Non-NF1 patients 
without surgical tumor reduction and/or nonsurgical treatment experienced similar deficits. Degree of hydroceph-
alus at diagnosis had no further impact. Psychomotor and processing speed were impaired comparably following 
chemo-/radiotherapy (P < .001–.021). Pretreatment factors such as NF1 or tumor site were relevant at multivariate 
analysis.
Conclusions. All pediatric LGG survivors are at risk to experience long-term cognitive impairments in various do-
mains. Even surgical only management of cerebellar LGG or no treatment at all, that is, biopsy only/radiological 
diagnosis did not protect cognitive function. Since pattern and extent of deficits are crucial to tailor rehabilitation, 
neuropsychological and quality of survival assessments should be mandatory in future LGG trials.
Long-term cognitive deficits in pediatric low-
grade glioma (LGG) survivors reflect pretreatment 
conditions—report from the German LGG studies
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Key Points
• Pediatric LGG compromises visual processing, motor function, and processing 
speed.
• Deficits occur independently of tumor site, major surgery, and degree of 
hydrocephalus.
• Survivors with NF1 fare worse. The tumor impacts more than adjuvant treatment.
Low-grade glioma (LGG) constitutes the largest group of 
pediatric brain tumors with high overall survival rates at 
10–20 years.1–4 Patients may suffer from a multitude of late 
effects, specifically cognitive impairments generally attrib-
uted to tumor site, surgical intervention, and complications 
as well as to nonsurgical treatment.5–9
Neuropsychological assessments of pediatric brain 
tumor survivors disclosed a wide range of late deficits in-
cluding reduced overall cognitive functioning and intel-
ligence, minor academic achievement, and lower income 
as well as inferior specific neuropsychological skills.10–12 
Cognitive late effects were found in survivors of high-
grade tumors and of LGG,13 that is, lower IQ score beside 
long-term health issues.5 Survivors were found to be at 
risk for deficits in neuropsychological dimensions such as 
attention, processing speed, executive functioning, visual-
spatial memory, language, and verbal short-term memory 
over time.14 Although some studies proved good func-
tional outcomes without severe quality of life (QoL) issues 
and few neurocognitive differences when comparing pa-
tients after treatment of cerebellar pilocytic astrocytoma 
to the healthy norm,15–17 impairments were detected when 
comparing LGG patients to high-achieving peers17 or their 
siblings.13
A large number of risk factors for the development of 
sequelae and possible predictors for cognitive decline in 
LGG patients have been identified5,14,18,19 including hy-
drocephalus,14,20 specific tumor sites,21,22 extent of sur-
gery, and nonsurgical treatment.13,14,23,24 LGG patients 
with Neurofibromatosis type 1 (NF1) are often already 
compromised by preexisting cognitive difficulties such 
as lower visual-motor integration and memory function. 
Nearly 1 of 2 patients meets the criteria for attention-deficit 
hyperactivity disease.25 Interpretation of results from cog-
nitive testing of LGG patients is often hampered by small 
patient series, widespread diagnostic time points,17,24,26 or 
variable outcome parameters, including an overreliance 
on full-scale IQ scores or adaptive behavior scales, which 
do not capture the full range of cognitive skills that may 
be affected by disease and treatment.23,27 Specifically, full-
scale IQ does not cover all essential outcome parameters.28
We analyzed cognitive assessments of German and 
Swiss LGG patients from the multicenter SIOP-LGG 2004 
study and LGG registry. Data were prospectively col-
lected in the neuropsychological accompanying study ap-
plying the German “Neuropsychological Basic Diagnostic” 
(NBD) screening tool with age-appropriate tests. We asked 
whether we were able to corroborate tumor location, sur-
gery, and pretreatment factors such as NF1 status and 
hydrocephalus as risk factors for cognitive late effects in 
a multicenter setting. We added results of longitudinal ob-
servation and following nonsurgical treatment.
Patients and Methods
Eligibility
The prospective, multinational, and multicenter SIOP-
LGG 2004 study29 registered patients with LGG of all sites 
from 2004 to 2012 and was continued in Germany as 
Importance of the Study
Reports on cognitive sequelae following pedi-
atric low-grade glioma (LGG) indicate tumor-
site, treatment and complications as risk factors. 
We analyzed prospectively collected neuropsy-
chological data of 316 German pediatric LGG 
patients applying the Neuropsychological Basic 
Diagnostic screening tool. At 2 and 5  years 
from diagnosis, we identified significant cog-
nitive impairments for the majority of patients 
with LGG at any site independent of neurofi-
bromatosis type 1 status. Deficits mainly af-
fected visual processing, motor function, and 
processing speed. They occurred (1) even fol-
lowing complete/subtotal resection of cere-
bellar LGG, (2) without nonsurgical treatment 
after biopsy/radiological diagnosis, and (3) were 
independent of the degree of hydrocephalus at 
diagnosis. In small subgroups, they did not de-
cline over time or differ between nonsurgical 
treatment modalities. Since type and extent of 
deficits are crucial to tailor adequate rehabilita-
tion programs, neuropsychological and quality 
of survival assessments should be mandatory 
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LGG registry until 2018. Inclusion criteria comprised age 
younger than 18  years, histologic diagnosis of LGG ac-
cording to the effective WHO classification, and no prior 
nonsurgical therapy. The radiologic diagnosis was ac-
cepted as an exception. A central review for pathology and 
radiology was recommended.
Informed consent was obtained from patients, parents, 
and/or guardians. The Institutional Review Board approved 
SIOP-LGG 2004 study and the LGG registry observed the 
Declaration of Helsinki in its revised version (Edinburgh, 
Scotland, 2000) and the WHO and European Community 
rules of “Good Clinical Practice” (effective January 17, 
1997).
Treatment Strategy
Following the SIOP-LGG 2004 study strategy 
(Supplementary Figure 1), the best safe resection of the 
primary tumor was recommended at diagnosis. Patients 
with complete resection were to be observed, as well as 
patients following incomplete resection, biopsy, or radio-
logical diagnosis if no threatening neurological symptoms 
were present. Severe initial symptoms or clinical/radiolog-
ical progression during observation indicated the start of 
nonsurgical treatment, if resection remained infeasible. 
Children younger than 8 years and all children with NF1 
were to receive primary chemotherapy. Older children of at 
least 8 years without NF1 were allowed to receive either pri-
mary radiotherapy or chemotherapy29 upon individual de-
cision at the local treatment center. Primary chemotherapy 
with vincristine and carboplatin for 18 months, without or 
with additional etoposide for randomized patients, was 
given as reported elsewhere.29 Radiotherapy was sched-
uled with a total dose of 54 Gy using either photons or 
protons. Brachytherapy/interstitial radiosurgery for suit-
able tumors was applied with 125-iodine seeds. Treatment 
for further clinical and radiologic progression was not 
standardized, but included all modalities following discus-
sion in local and reference tumor boards.
Neuroimaging at Diagnosis and Follow-up
Neuroimaging at diagnosis (including the grading of hy-
drocephalus, Supplementary Figure 2), following sur-
gical interventions, assessing the response of nonsurgical 
treatment, and during the further course of disease fol-
lowed recommendations of the German pediatric brain 
tumor network and published consensus and is detailed in 
Supplementary Materials.
Neuropsychological Basic Diagnostic
The neuropsychological accompanying study included pa-
tients from the SIOP-LGG 2004 study and the LGG registry 
for a screening of basic neuropsychological functions with 
the German NBD. Assessments were scheduled at diag-
nosis (T0), approximately 2 years after diagnosis (T1), that 
is, following end of first-line treatment for those receiving 
adjuvant therapy, and during follow-up about 5 years after 
diagnosis (T2). The assessment periods for T1 and T2 were 
1;6-3;6 years and 3;7-6;6 years, respectively. Anonymized 
data were forwarded to the study center.
The NBD screening tool is based on the Cattell–
Horn–Carroll (CHC) model for intelligence30 and the 
concept of cross-battery assessment (XBA).31 The CHC 
model represents intelligence in several major domains 
(Supplementary Figure 3), most of which can be tested by 
age-appropriate tests. Cognitive domains represented in 
the NBD include fluid intelligence (Gf), visual processing 
(Gv), verbal short-term memory (Gsm), crystallized in-
telligence (Gc), psychomotor speed (Gps), and cognitive 
processing speed or selective attention (Gs) (Table  1). 
The NBD is a modified version of the “Wuerzburger 
psychologische Kurzdiagnostik (WUEP-KD)” developed 
  
Table 1. Domains and Tests of the Neuropsychological Basic Diagnostic (NBD) Screening
CHC Domain Test Age Range of Test 
(years; months)
Fluid intelligence (Gf) Raven’s Coloured Progressive Matrices (CPM) 6; 0–10; 11
Raven’s Standard Progressive Matrices (SPM) from 11; 0
Crystallized intelligence (Gc) Picture Naming subtest  
Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI-III)
4; 0–5; 11
Vocabulary subtest  
Wechsler Intelligence Scale for Children IV (WISC-IV)
6; 0–16; 11
Vocabulary subtest  
Wechsler Intelligence Scale for Adults (WAIS-III)
from 17; 0
Verbal short-term memory (Gsm) Subtest Number Recall  
Kaufman Assessment Battery for Children II (K-ABC II)
4; 0–18; 11
Visual processing (Gv) The Beery-Buktenica Developmental Test of Visual-
Motor Integration (VMI)
from 4; 0
Psychomotor speed (Gps) Purdue Pegboard test (Pegboard) from 5; 0
Cognitive processing speed or selective  
attention (Gs)










niversitatsbibliothek user on 10 D
ecem
ber 2020
 4 Traunwieser et al. Cognitive deficits in pediatric LGG survivors
by Ottensmeier et al.32 using the XBA by combining dif-
ferent tests and subtests to feasibly measure primary 
cognitive abilities.
Assessments from non-NF1 and NF1 patients included 
in this report had to meet the following criteria: (1) pa-
tient age of at least 4 years at neuropsychological assess-
ment, (2) adequate visual acuity to be able to participate, 
(3) intracerebral primary LGG, (4) no concurrent chemo-
therapy treatment, (5) no record of premorbid neurolog-
ical or psychiatric diseases (ie, psychiatric disorders such 
as obsessive–compulsive disorder, depression, or psy-
chotic symptoms interfering with the completion of the 
tests), and (6) no compromising neurologic symptoms at 
the time point of assessment (ie, the Beery-VMI cannot be 
completed in the case of severe ataxia, hemiparesis, or 
visual impairment), no tumor progression or oncologic 
long-term complications.
Younger or visually impaired patients not eligible for 
the test material were excluded. As well, patients who 
had had impairing immediate postoperative neurolog-
ical complications, such as unresolved postoperative 
pediatric cerebellar mutism syndrome, and those under 
chemotherapy were excluded in order not to distort the 
results.
Statistics
For continuous variables, the median and range are given. 
Categorical variables are indicated in absolute or relative 
frequencies.
Results from the NBD were compared with norma-
tive data for each test with correction for age. The re-
sults are reported as standard scores (SS, mean x ̅ = 100 
and standard deviation [SD] = 15). We performed a one-
sample t test or Wilcoxon test to compare the data with 
expected population scores. We computed t test for pa-
tient subgroups or Mann–Whitney U test, if the data did 
not meet the necessary criteria for a t test (normal dis-
tribution of data; n > 20). Longitudinal data were ana-
lyzed using paired t test or Wilcoxon signed-rank test. For 
multiple comparisons, we adjusted the P value using the 
Bonferroni–Holm method to control for family-wise error 
rate at level alpha. Analysis of variance (ANOVA) was per-
formed for group differences. Welch’s F was computed if 
data did not meet homogeneity criteria for an ANOVA.33 
Effect sizes were performed using Cohen’s d; d ≥ 0.8 was 
considered a highly relevant effect.34 Multivariate analysis 
of covariance was also computed for group differences 
and to control for the variables sex and age at diagnosis. 
Pillai’s Trace criterion was used instead of Wilk’s λ, if un-
equal covariance matrices were detected. Effect sizes 
were performed using η2par; η
2
par ≥ 0.06 was considered 
a medium relevant effect.34 Expectation-maximization 
algorithm was computed to account for the problem of 
missing data.
Analyses were exploratory, and P values were con-
sidered as descriptive measures to detect and study 
meaningful effects. In particular, no significance level was 
fixed. P values less than .05 were considered statistically 




Thirty-eight participating pediatric oncology centers in 
Germany and Switzerland used the NBD in the course of 
standard follow-up care and reported results from cogni-
tive assessments for 339 patients from the SIOP-LGG 2004 
study and LGG registry in the period between March 12, 
2009 and February 16, 2017; patients had their tumor diag-
nosis before December 31, 2014.
Reports of 316 LGG patients met the criteria for further 
analysis. Twenty-three reports were excluded for tumor lo-
cation in the spinal cord (n = 9), presence of NF2 (n = 1), 
radiologic diagnosis of LGG not confirmed by central re-
view (n = 2), and concurrent treatment while tested (n = 5), 
no data forwarded (n = 4), not tested within the fixed T1/T2 
intervals (n = 2).
Epidemiologic data are given in Table 2 and compared 
to all other study patients diagnosed within that period in 
Supplementary Table 1. The group of patients tested with 
the NBD screening tool has a comparable median age, sex 
distribution, and a portion of NF1 patients, but contains 
more patients in the higher age group, with cerebellar tu-
mors, and PA histology. Epidemiologic details for further 
subgroups are compiled in Supplementary Tables 2–5.
The median age at diagnosis was 7.1  years. NF1 was 
diagnosed clinically in 45 patients. Primary dissemination 
was present in 7 patients. In 12 patients, tumors later pro-
gressed with dissemination.
Tumor location was in the cerebral hemispheres for 
49/316 (16%) and the supratentorial midline for 123/316 
patients (39%), including 60/123 tumors in the visual path-
ways and 11/123 in the thalamus. Infratentorial tumors 
(144/316, 45%) comprised cerebellar (121/144) and brain-
stem tumors (23/144) analyzed together in order to avoid 
undersized groups. The subgroup of patients with com-
pletely or subtotally resected infratentorial tumors con-
tained 6 with brainstem tumors. The cohort of survivors 
of cerebellar tumors was divided for tumor location in the 
vermis (56/118) and the left and right hemispheres (29/118 
and 30/118, respectively; 3/118 no information).
Histologic review confirmed pilocytic astrocytoma in the 
majority of all patients (191/316, 60%). Neuroradiological 
criteria justified the diagnosis of an LGG in 61 patients, 
(NF1: 30/61; non-NF1 31/61 with 16 visual pathways, 4 di-
encephalon, 5 hemispheres, 6 cerebellum and caudal 
brainstem).
For half of the non-NF1 cohort extent of initial resec-
tion was complete or subtotal (136/271). A slight majority 
(137/271, 51%) had infratentorial tumors. Prior to cognitive 
testing, 44/271 patients (16%) had 2 or more resections.
Nonsurgical treatment had been given to 96 patients 
prior to NBD testing (30%). Sixty-five patients received 
chemotherapy (27/65 NF1), while 31 (1/31 NF1) had 
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Table 2. Epidemiologic Data
All (n = 316) Non-NF1, All Sites  
(n = 271)
Non-NF1, Posterior Fossa  
(n = 137)
Median age at diagnosis (years, range) 7.1 7.5 6.0
0.2–17.5 0.2–17.5 0.4–16.8
Median age at assessment T1 (years, range) 9.9 10.0 8.3
4.0–20.6 4.0–20.6 4.0–19.8
Median age at assessment T2 (years, range) 11.9 12.5 11.6
4.0–21.8 4.0–21.8 4.0–21.7
Age group at diagnosis
 <1 year 7 7 2
 1-7 years 167 135 82
 ≥8 years 142 129 53
Sex    
 Male 166 145 74
 Female 150 126 63
Tumor localization
 Supratentorial 172 134 —
  Cerebral hemispheres (right/left/both) 49 (28/19/2) 48 (27/19/2) —
  Supratentorial midline 123 86 —
   Visual pathways 60 32  
   Thalamus 11 11  
   Other SML 52 43  
 Infratentorial 144 137 137
  Cerebellum (right/left/vermis/nn) 121 (30/31/57a/3) 118 (30/29/56a/3) 118 (30/29/56a/3)
  Caudal brainstem 23 19 19
Hydrocephalus at diagnosis
 None 133 100 40
 Minor 38 35 13
 Moderate 82 77 48
 Severe 21 20 10
 No information 42 39 26
Shunt implantation
 Third ventriculostomy 21 20 2
 VP shunt 50b 42b 19b
 Other 1 1 0
 No shunt 243 208 116
 No information 1 0 0
Histology
 PA 191 178 117
  PA WHO grade I 187 174 116
  PMA 4 4 1
 SEGA 1 1 0
 Glioneuronal tumors WHO grade I 36 36 10
  GG 27 27 9
  DIG 2 2 0
  DNT 5 5 0
  RGNT 2 2 1
 Diffuse glioma WHO grade II 15 14 4
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chemotherapy without (12/38) or with (26/38) prior tumor 
volume reduction, and 10/38 had also salvage treatments in-
cluding radiotherapy in 7/10 patients. Primary radiotherapy 
was applied in 30/271 non-NF1 patients (18 photons, 2 
protons, and 10 brachytherapy), 27/30 had surgical tumor 
volume reduction before radiotherapy, and 1/30 had addi-
tional salvage treatments for subsequent progression.
Radiologic grading classified hydrocephalus at di-
agnosis in non-NF1 patients with posterior fossa (PF) 
tumors as minor in 13/137, moderate in 48/137, and se-
vere in 10/137 patients (40/137 without hydrocephalus; 
26/137 no information). A permanent shunting procedure 
(ventriculoperitoneal) and/or third ventriculostomy was 
documented for 21/137 patients with infratentorial and 
for 41/134 with supratentorial tumors at diagnosis or fol-
low-up (1/134 no information).
Results of NBD
Analysis of neuropsychological impairments included sep-
arate T1 and T2 results. Both time points were combined 
All (n = 316) Non-NF1, All Sites  
(n = 271)
Non-NF1, Posterior Fossa  
(n = 137)
 LGG nos 8 7 3
 Nondiagnostic biopsy 4 3 0
 No histology 57 28 3c
First surgery before NBD screening (including ChT and RT patients)
 Complete resection 104 103 71
 Subtotal resection 34 33 24
 Partial resection 63 59 29
 Biopsy 52 45 10
 No surgery 63 31 3c
Number of resections before NBD
 1 205 196 111
 2 42 40 21
 >2 6 4 2
 None 63 31 3c
Interventions before NBD
 Surgery only 189 183 121
  Biopsy only 12 11 3
  Tumor reduction only 177 172 118
 Primary chemotherapy 65 38 6
  1 53 28 5
  >1 (no RT) 5 3 0
  >1 (including RT) 7 7 1
 Primary radiotherapy 31 30 7
  RT only 30 29 7
  RT and salvage chemotherapy 1 1 0
 No intervention/intervention after NBD 31 20 3c
N for time point of assessment
 T1 149 128 64
 T2 203d 174d 90d
SML, supratentorial midline; PA, pilocytic astrocytoma; PMA, pilomyxoid variant; SEGA, subependymal giant cell astrocytoma; GG, ganglioglioma; 
DIG, desmoplastic infantile ganglioglioma; DNT, desmoplastic neuroepithelial tumor; RGNT, rosette-forming glioneuronal tumor; PXA, pleomorphic 
xanthoastrocytoma WHO grade II; LGG nos, low-grade glioma not otherwise specified; ChT, chemotherapy; RT, radiotherapy.
aIncluding n = 2 tumors with bilateral hemispheric involvement and n = 5 with “cerebellar midline” designation.
bVP shunt after third ventriculostomy: n = 4 for all patients; n = 3 for non-NF1 patients; n = 0 for posterior fossa patients.
cCerebellar tumors without histologic confirmation (n = 3): junction of cerebellar peduncle and medulla oblongata, right cerebellar peduncle, right 
cerebellar hemisphere, and vermis.
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for 2 subgroup comparisons to avoid undersized groups. 
Results of the NBD testing are compiled in Table 3 (com-
pared to the expected population score) and Table 4 (group 
comparisons), and raw data given in Supplementary Tables 
6 and 7 (mean with standard deviation, median with inter-
quartile range). Results of multivariate analysis are sum-
marized in Tables 5–7.
A separate analysis was performed for the small and het-
erogeneous group of 36 patients, who were tested at both 
time points; results for 31 non-NF1 patients are summar-
ized in Supplementary Table 8.
NBD T0 data were incomplete and difficult to assess 
in most hospitals and are listed for information only 
(Supplementary Table 9).
Influence of NF1 status on cognitive performance.—
Analysis disclosed statistically significant impairments for 
45 patients with NF1 with respect to Gsm at T1 (P < .001; 
d = 0.89) and Gsm and Gv at T2 (P < .001–.021; d = 0.66–1.03) 
when compared to 271 patients without NF1 (Figure  1A 
and B). When compared to the expected population score, 
271 non-NF1 patients showed statistically noticeable lower 
results for Gv, Gps, and Gs at T1 (P < .001; d = 0.37–1.80) 
and for Gf, Gv, Gps, and Gs at T2 (P < .001; d = 0.36–1.91).
Additional multivariate analysis confirmed a significant 
effect for NF1 status versus non-NF1 (Wilk’s λ = 0.87, F (8, 
305) = 5.67, P < .001), with a medium effect size (η2par = 0.13) 
controlling for age at diagnosis and sex. Univariate test 
statistics indicated a significant effect of NF1 on Gf (F (1, 
312) = 7.45, P = .038) with a small effect size (η2par = 0.02), 
on Gc (F (1, 312) = 5.54, P =  .019) with a small effect size 
(η2par = 0.02), on Gsm (F (1, 312) = 20.59, P < .001) with a me-
dium effect size (η2par = 0.06), and on Gv (F (1, 312) = 26.02, 
P < .001) with a medium effect size (η2par = 0.08). Pairwise 
comparisons confirmed that NF1 patients achieved signif-
icantly lower scores in these domains than non-NF1 pa-
tients (Gf: ∆Madj.= 7.10, SE = 2.60, P = .007; Gc: ∆Madj = 6.20, 
SE = 2.63, P = .019; Gsm: ∆Madj.= 10.49, SE = 2.31, P < .001; 
Gv: ∆Madj = 10.12, SE = 1.98, P < .001).
Influence of length of observation time (longitudinal 
cognitive performance).—Results from both assess-
ments (T1 and T2) were available for 31 non-NF1 patients. 
Their median age at diagnosis was 6.13  years. Most tu-
mors were located infratentorially (n = 17), 11 were in the 
supratentorial midline, only 3 were hemispheric. While 23 
patients had been observed only (4 without histologic con-
firmation), 5 patients had received chemotherapy and 3 
received radiotherapy prior to testing. Test results of this 
heterogeneous subgroup showed no differences from T1 
to T2.
Influence of site in non-NF1 patients on cognitive 
performance.—Upon comparison of the neuropsycholog-
ical performance of non-NF1 patients with supratentorial 
hemispheric (n = 48), supratentorial midline (n = 86), and 
infratentorial tumor sites (n = 137), group differences were 
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Figure 1. Bar graphs for the main results of the NBD screening. (A) T1 bar graphs for statistically noticeable results for NF1 patients versus 
non-NF1 patients; (B) T2 bar graphs for statistically noticeable results for NF1 patients versus non-NF1 patients; (C) T1 and T2 bar graphs for sta-
tistically noticeable results for non-NF1 patients with infratentorial tumors and complete or subtotal tumor resection; (D) T1 and T2 bar graphs for 
statistically noticeable results for non-NF1 patients without surgical tumor volume reduction and no adjuvant chemo- or radiotherapy; (E) T1 and 
T2 bar graphs for statistically noticeable results for non-NF1 patients following chemotherapy; (F) T1 and T2 bar graphs for statistically noticeable 








niversitatsbibliothek user on 10 D
ecem
ber 2020











hand (P =  .027; d = 0.36) and coordination of both hands 
(P  =  .014; d  =  0.49), as survivors with infratentorial loca-
tions showed the lowest mean score when compared 
to survivors of the other tumor sites. Further differ-
ences were detected for Gc (P =  .032; d = 0.75) with sur-
vivors of supratentorial hemispheric tumors displaying 
the lowest mean score when rivaled to infratentorial and 
supratentorial midline sites. Additional comparison of 
left-sided supratentorial hemispheric tumors (n  =  19), 
supratentorial midline (n = 86), and infratentorial tumors 
(n  =  137) regarding Gc showed statistically noticeable 
differences (P  =  .011; d  =  0.75) with lowest mean score 
for survivors of left-sided supratentorial hemispheric tu-
mors. Analysis of survivors of right-sided supratentorial 
hemispheric tumors (n  =  27), supratentorial midline and 
infratentorial tumors regarding Gc displayed no statisti-
cally noticeable differences between groups.
Multivariate analysis validated no significant effect of 
localization on cognitive performance, but indicated an 
interaction between therapy prior to NBD screening and lo-
calization (Pillai’s Trace = 0.27, F (48, 1416) = 1.40, P = .039), 
with a small effect size (η2par = 0.05).
Univariate test statistics had shown a significant main ef-
fect of localization on Gf (F (2, 238) = 4.09, P = .018) with a 
small effect size (η2par = 0.03) and on Gv (F (2, 238) = 4.37, 
P = .014) with a small effect size (η2par = 0.04). As indicated 
by pairwise comparisons, these main effects resulted 
from significantly lower scores for Gf in patients with 
supratentorial hemispheric tumors compared to patients 
with infratentorial tumors (∆Madj = 14.48, SE = 5.59, P = .31). 
Furthermore, regarding Gv, patients with supratentorial 
hemispheric tumors achieved significantly lower scores 
than patients with infratentorial tumors (∆Madj  =  11.95, 
SE = 4.16, P =  .13), as well as lower scores compared to 
patients with supratentorial midline tumors (∆Madj = 9.80, 
SE = 3.71, P = .27).
Univariate test statistics for the interaction of therapy 
before NBD screening and localization indicated a sig-
nificant effect on Gv (F (6, 238) = 2.19, P = .045), with a 
small effect size (η2par = 0.05). The interaction effect was 
due to the fact that, on average, radiotherapy patients 
with supratentorial hemispheric tumors achieved lower 
scores on Gv (Madj = 70.35, SD = 8.46) than radiotherapy 
patients with supratentorial midline (Madj  =  97.01, 
SD  =  3.24) or with infratentorial tumors (Madj  =  95.84, 
SD = 5.14).
Influence of infratentorial tumor site and extent of resec-
tion in non-NF1 patients on cognitive performance.—
NBD results for non-NF1 patients with infratentorial tumor 
site (137/271) revealed no significant univariate or multi-
variate effect of tumor site within the PF.  Yet, univariate 
test statistics indicated a significant main effect of ex-
tent of resection on Gps of the nondominant hand (F (3, 
88) = 3.30, P = .24), with a medium effect size (η2par = 0.10) 
and on Gps of coordination of both hands (F (3, 88) = 3.22, 
P = .027), with a medium effect size (η2par = 0.10). Pairwise 
comparisons indicated that these effects resulted from sig-
nificantly lower scores for Gps of the nondominant hand 
(∆Madj  =  19.39, SE  =  6.55, P  =  .024) and for Gps of both 
hands (∆Madj = 19.52, SE = 5.82, P = .007) of patients with 
partial versus patients with complete or subtotal tumor 
resection.
Still, patients with infratentorial LGG and complete 
or subtotal resection prior to NBD testing (95/137; 69%) 
showed statistically noticeable impairments compared to 
the expected population score in Gv, Gps, and Gs at T1 (P < 
.001; d = 0.58–2.38) and of the same dimensions and effect 
size at T2 (P < .001–.008; d = 0.45–1.73; Figure 1C).
In addition, 43/95 patients with cerebellar vermian tu-
mors showed larger statistically noticeable impairments 
at T1 in Gps for coordination of both hands (P  =  .048; 
d  =  0.92) as compared to 43/95 patients with tumors of 
cerebellar hemispheric location. When comparing right 
and left cerebellar hemispheres no differences were de-
tected. However, for combined time points the comparison 
of vermian versus right versus left cerebellar site revealed 
significant differences for Gps of the nondominant hand 
and coordination (P = .012–.035; d = 0.70–0.79).
Multivariate analysis showed no significant multivariate 
effect for the interaction between infratentorial subsites 
and extent of resection, while univariate tests indicated a 
significant interaction between infratentorial subsites and 
extent of resection on Gps of the nondominant hand (F (6, 
88) = 2.37, P = .036), with a medium effect size (η2par = 0.14). 
The interaction effect resulted from lower score in pa-
tients with left hemispheric tumors and partial resection 
(Madj = 33.34, SD = 11.60) as compared to patients with left 
hemispheric tumors and biopsy (Madj = 57.73, SD = 20.98) 
and to patients with complete or subtotal tumor resec-
tion (Madj = 82.96, SD = 5.73). Likewise, patients with right 
hemispheric tumors and partial resection (Madj  =  64.83, 
SD = 10.61) showed lower scores than patients with right 
hemispheric tumors and complete or subtotal resection 
(Madj  =  82.75, SD  =  5.98) and patients receiving biopsy 
only (Madj  =  103.73, SD  =  21.27). Patients showed sig-
nificant impairments at T1 in Gv (P = .041; d = 1.53) if the 
tumor was located left-sided (14/29) as compared to right-
sided (15/29). No differences were detected between the 
cerebellar subsites at T2.
For 11/31 non-NF1 patients with completely or subtotally 
resected infratentorial tumors and paired assessments at 
T1 and T2, no differences were noted between results of 
the 2 time points.
Influence of hydrocephalus at diagnosis in PF tumor 
survivors on cognitive performance.—Patients with PF 
tumors that had moderate/severe hydrocephalus (n = 58) 
displayed significant worse Gf at T1 (P  =  .032; d  =  0.78) 
when compared with 53 patients with no/minor hydro-
cephalus (information available for 111/137 patients). No 
differences were detectable at T2. Of 111 patients, 17 re-
ceived shunting procedures.
Univariate tests indicated a significant effect of hydro-
cephalus on Gc (F (1, 88) = 5.80, P = .018), with a medium 
effect size (η2par = 0.06). Multivariate analysis displayed no 
multivariate effect for hydrocephalus at diagnosis and pair-
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Yet, multivariate test statistics indicated a signifi-
cant effect for the interaction between infratentorial 
subsites and degree of hydrocephalus (Wilk’s λ  =  0.65, 
F (24, 236)  =  1.60, P  =  .039), with a medium effect size 
(η2par  =  0.14). For these parameters, univariate tests in-
dicated a significant effect on Gc (F (3, 88)  =  3.35, 
P  =  .023) with a medium effect size (η2par  =  0.10) and 
Gsm (F (3, 88) = 3.01, P = .035) with a medium effect size 
(η2par  =  0.09); however, pairwise comparisons revealed 
subgroup mean scores within the norm.
Influence of management on cognitive performance.—
Observation group
Thirty-one non-NF1 survivors with tumors in supratentorial 
hemispheric (5/31), supratentorial midline (20/31), and 
infratentorial locations (6/31) without surgical tumor 
volume reduction (radiological diagnosis n  =  20, biopsy 
n = 11) and no adjuvant chemo- or radiotherapy had sta-
tistically noticeable lower results in Gps and Gs at T1 (P < 
.001–.030; d = 0.65–0.85) and at T2 (P = .008; d = 0.88) com-
pared to the expected population score (Figure 1D). Of 31, 
14 had moderate/severe hydrocephalus and 12/31 had per-
manent shunting procedures.
Chemo- and radiotherapy groups
The relevant discrepancy of patient age between the 2 
non-NF1 treatment groups (Supplementary Table 4) 
precluded direct group comparison. Compared to the 
expected population score the chemotherapy group 
demonstrated lower scores for Gps and Gs at T1 and T2 
(P < .001–.020; d = 1.99–3.50) and for Gv at T2 (P = .032; 
d  = 1.42). The radiotherapy group scored lower for Gps 
of the nondominant hand and Gs at T1 and T2 (P = .008–
.030; d = 1.87–3.74), for Gps of the dominant hand at T2 
(P = .021; d = 2.06), and for coordination of both hands at 
T1 (P = .014; d = 3.14; Supplementary Table 10; Figure 1E 
and F).
Multivariate analysis of non-NF1 patients showed no 
significant multivariate influence of the respective treat-
ment arms before NBD screening, though univariate test 
statistics indicated a significant main effect of therapy 
on Gv (F (2, 238) = 2.85, P = .038), with a small effect size 
(η2par  = 0.04). Again, pairwise comparisons revealed sub-
group mean scores within the norm.
The significant multivariate effect for the interaction be-
tween treatment arms, localization, and extent of resec-
tion (Pillai’s Trace = 0.23, F (32, 936) = 1.74, P = .007) has a 
medium effect size (η2par = 0.06), while univariate test sta-
tistics indicated a significant effect for this interaction on 
Gsm (F (4, 238) = 3.01, P = .019), with only a small effect size 
(η2par = 0.05). However, there were no or too few cases in 
various combinations of factor levels.
Discussion
Results of cognitive testing within our prospectively regis-
tered cohort that followed the comprehensive treatment al-
gorithm of the SIOP-LGG 2004 protocol point to significant 
reductions in nearly all domains of cognitive performance 
(if compared to the normative population). They stress the 
negative impact of NF1 as well as of hydrocephalus at diag-
nosis for infratentorial tumors in non-NF1 patients and the 
impact of tumor site in its relation to the extent of surgery.
Cohort and Assessment Comparison
Our cohort is well comparable to other LGG cohorts with 
respect to age, sex distribution, NF1 status, tumor location, 
and histology,2–4 but excluded very young patients due to 
the premises of the NBD test battery. Corresponding to the 
defined time points of cognitive assessment 2 and 5 years 
after diagnosis the cohort grew older. Yet, only a few 
(n = 36, 31/36 non-NF1) patients were examined at both oc-
casions limiting statements about individual longitudinal 
development.
In view of the heterogeneous spectrum of pediatric LGG 
with respect to age, NF1 status, tumor site, and treatment, 
results of limited patient numbers have to be interpreted 
with caution for significance.15,17,26 Analysis of neuropsy-
chological sequelae has to implement distinct cognitive 
outcome variables apart from full-scale IQ score, which 
are essential for the quality of survival (QoS) and neuro-
psychological functioning, while remaining brief in exe-
cution.28 Otherwise, smaller centers may have problems 
to implement full neuropsychological assessment due to 
restricted resources.35 Still, brief assessments as the NBD 
meet satisfying psychometric criteria for valid analysis 
of cognitive functioning.32 Specific time points of assess-
ments are important because of time-related effects of 
cognitive decline such as “growing into deficit.” 36 Current 
recommendations from the Children’s Oncology Group 
and the SIOP-E Brain Tumor Group for analysis of neuro-
psychological late effects include a broad but brief assess-
ment of cognitive functions.37–39 Our results are based on 
a representative sample size, an assessment approach for 
specific aspects of the CHC model, and distinct diagnostic 
time points.
Impact of NF1 Status
Deficits in memory, attention, visual-spatial functions, 
and lower IQ score were reported in NF1 patients without 
brain tumors,25 but had been apparent for IQ scores upon a 
comparison of patients with LGG with and without NF1, as 
well.5 Our cohort showed noticeably different results from 
the expected population scores in various domains across 
both time points. Nevertheless, the majority of non-NF1 
LGG survivors displays scores within normal limits of 1 SD 
from the population mean for most dimensions except for 
fine motor skills and processing speed. A comparison of 
results of LGG patients affected by NF1 and without NF1 
corroborates statistically noticeable differences of cog-
nitive function for verbal short-term memory and visual-
motor integration with lower scores in the NF1 cohort.36,40 
Additionally, lower scores for NF1 versus non-NF1 patients 
were confirmed for fluid and crystallized intelligence, 
verbal short-term memory, and visual processing by mul-
tivariate analysis. For crystallized intelligence, however, 
there is only a small effect and mean scores for both NF1 
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series, the majority of NF1 patients had visual pathway 
glioma (28/45) and no primary surgery (32/45), but 60% 
(27/45) received standard chemotherapy for progres-
sion. Results for visual-motor integration were noticeably 
lower for the small subgroup of NF1 patients with visual 
pathway glioma following chemotherapy as compared to 
the population norm.41 Chemotherapy-associated changes 
in fractional anisotropy are increased in NF1, and these 
white matter changes may contribute to the differences in 
cognitive results.42 Within our older cohort, we could not 
replicate reports on language difficulties in young children 
with NF1 as stressed by Brei et al.43 This may be due to spe-
cific support for dyslectic children in the German school 
system.44
Impact of Tumor Site, Resection, and 
Hydrocephalus in Non-NF1 Patients
Reports on the role of location stressed that patients 
with tumors of the cerebral hemispheres experience the 
greatest impairment in cognitive functioning.18 Comparing 
patients with hemispheric, midline, and brainstem LGG 
within the first year after surgery, Ris et al.45 reported no 
differences in cognitive functions, though—consistent 
with the functional organization of the brain—patients 
with left hemispheric tumors were at significantly greater 
risk for lower scores of language functions (verbal IQ and 
communication) than patients with right hemispheric tu-
mors. Upon long-term surveillance, significantly more 
impairment of verbal functions was revealed in survivors 
of supratentorial tumors, whereas interaction with age 
and treatment had been ruled out.13 Comparison of re-
sults from our subgroups with either supratentorial hem-
ispheric, supratentorial midline, or infratentorial tumors 
did show significant results concerning impairments in 
language functions for our patients with supratentorial 
hemispheric sites, more pronounced for survivors with 
left-sided tumors, thus supporting the fact of relevant 
language impairment in supratentorial tumor sites. 
Multivariate analysis additionally revealed impairments 
for survivors of supratentorial hemispheric tumors in fluid 
intelligence and visual processing, further underlining the 
more pronounced deficits in patients with tumors of the 
cerebral hemispheres.18 For this subgroup, the portion of 
patients with chemo- (n  =  2) and/or radiotherapy (n  =  2) 
was too small to permit separate analysis.
On the other hand, results of psychomotor functioning 
were lower for our patients with infratentorial tumors as 
compared to other locations, reflecting the specific func-
tional key position of this area of the brain. Deficits in pa-
tients with completely or subtotally resected cerebellar 
LGGs without adjuvant treatment were compiled in several 
reports and included problems regarding sustained atten-
tion, processing speed, language, visual-spatial functions, 
executive functioning, memory, as well as behavioral prob-
lems, motor dysfunction, and an increased proportion of 
reduced full-scale IQ.13,23,24 Motor deficits were already ap-
parent within the first year after cerebellar tumor surgery in 
the series of Beebe et al.27 with largest effect sizes in those 
cognitive exams that required motor responses. Their re-
sults could not relate deficits to tumor location within the 
cerebellum or pre-, peri-, and postsurgical factors.27 Within 
our patient series, complete or subtotal resection of cer-
ebellar LGG without adjuvant treatment was followed by 
impairments in visual processing, psychomotor speed, 
and processing speed/selective attention. The pattern of 
neuropsychological and cognitive late effects of cerebellar 
LGG has been described as a cerebellar cognitive affec-
tive syndrome (CCAS).46 The CCAS includes sequelae in 
visual-spatial functions, language, memory, and regulation 
of affect, which are also apparent in children47 and asso-
ciated with tumor location in the vermis21 and in the left 
cerebellar hemisphere.22 More pronounced deficits in cog-
nitive function and fine motor skills were correlated with 
tumors of the cerebellar vermis21 and in visuospatial func-
tions with LGG of the left cerebellar hemisphere,22 as well.
In our cohort of non-NF1 patients with completely or 
subtotally resected infratentorial tumors, those with tu-
mors in the vermis experienced greater deficits in psy-
chomotor speed than those with tumors in the cerebellar 
hemispheres 2  years after diagnosis, while these differ-
ences were no longer detectable at 5  years. A  compar-
ison of results between patients with tumors of the left or 
right cerebellar hemispheres did not reveal differences, 
though results were still inferior to the population norm. 
Thus, we did not observe recovery or further decline of 
neurocognitive function beyond T1 for survivors of all PF 
sites. At this time point, median scores for vermian and 
hemispheric locations align, mostly displaying a down-
ward trend (Supplementary Table 7), whereas within the 
small subgroup with consecutive assessments no differ-
ences between the results at 2 and 5 years were detected. 
This argues against profound recovery, while improved 
performance within the first year after diagnosis was 
reported.20
The results of the multivariate analysis indicated 
no differences in cognitive function between patients 
with vermian and both cerebellar hemispheric tumors. 
Nevertheless, the extent of resection impacted fine motor 
skills with the lowest scores for survivors with partially re-
sected LGG of the left cerebellar hemisphere. Yet, patients 
with completely/subtotally resected tumors achieved re-
sults below normal, as well. Our results support previous 
findings of cognitive sequelae in LGG patients following 
complete and subtotal resection of cerebellar LGG.5,13,14 
They correspond to the concept of “growing into deficit,” 36 
which should be borne in mind for all LGG patients, espe-
cially those with few apparent cognitive difficulties after 
complete or subtotal surgery.
Patients with infratentorial tumors and moderate or se-
vere hydrocephalus at diagnosis experienced no signif-
icant additional constraints except for fluid intelligence 
2 years after diagnosis compared to those without or with 
minor signs of increased intracranial pressure at diagnosis. 
Yet, both results are still within the norm, while psycho-
motor and processing speed are significantly lower than 
the expected population score at both time points.
Reports on cognitive sequelae following biopsy or 
radiological diagnosis in LGG are scant. Compromise 
of supratentorial white matter and the intellectual out-
come was reported by Liu et  al.48 for a smaller patient 
subgroup. These effects occurred in the wake of hydro-
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surgery with tumor infiltration into healthy tissue or 
compression and subsequent damage of healthy tissue 
by mass effect.48 Reduction of normal-appearing white 
matter was linked to reduced cognitive functioning19,49 
and was observed in survivors of high-grade tumors fol-
lowing intensive treatment,19 but even in LGG patients 
treated without radiotherapy48 or chemotherapy.50 In 
our patients, when compared to the expected popu-
lation score, cognitive sequelae concerning psycho-
motor and processing speed/selective attention were 
detected in patients without relevant tumor reductive 
surgery besides biopsy and in those with radiological 
diagnosis only.
Neuropsychological late effects in cerebellar LGG pa-
tients and patients without adjuvant treatment are often 
“overlooked” due to conflicting results from studies and 
seemingly uneventful oncological treatment. We would 
underline that they deserve scrutinous neuropsycholog-
ical surveillance for long-term cognitive outcomes and 
adequate rehabilitation to the same degree as patients 
receiving more intensive treatments to optimize their 
outcomes.45,51
Impact of First-Line Nonsurgical Treatment on 
Cognitive Performance
The use of chemotherapy for LGG instead of radiotherapy 
was encouraged by reports about declining IQ scores 
during long-term observation, especially in younger pa-
tients and patients with NF1, despite the conformal radia-
tion therapy.6,52 As a consequence, younger patients and 
all NF1 patients are currently rather allocated to chemo-
therapy,53 as in our study, and NBD results of the 2 treat-
ment modalities cannot be compared directly. For both 
nonsurgical treatment groups, psychomotor and proc-
essing speed are significantly impaired at 2 and 5 years 
following the treatment. These results align with other 
reports.48,54 Weaknesses in verbal working memory, psy-
chomotor speed, visual perception, attention, and proc-
essing speed as well as overall cognition were reported 
for pediatric LGG patients treated without radiotherapy.54 
Among causative predictors of cognitive deficits, multiple 
surgical interventions, hydrocephalus, shunting proced-
ures, NF1 status, and supratentorial tumor location were 
identified besides chemotherapy.48,54 Lower 5-year scores 
for the younger non-NF1 chemotherapy cohort in our re-
port should be commented cautiously as nonsurgical 
treatment started at individual time points following di-
agnosis. Thus, the interval between nonsurgical treat-
ment and NBD testing varies, and lower scores do not 
invariably indicate declining abilities over time. Almost 
a quarter of our chemotherapy patients had more than 
one treatment line, including radiotherapy for some. Our 
study cannot answer the question, if the preferred use of 
chemotherapy instead of early radiation in younger pa-
tients will be beneficial for cognitive outcome; however, 
the current mode of treatment allocation results in a 
comparable pattern of deficits and supports the demand 
to focus on more parameters besides radiation-induced 
injury.48–50
Limitations of Our Report
This report comprises a significant patient cohort, fol-
lowing a comprehensive treatment strategy, but allows 
cautious interpretation of results only.
• The NBD program was added to the SIOP-LGG 2004 
brain tumor trial in 2009 and continued with the LGG 
registry without a predefined research question.
• It was performed in a large number of German and 
Swiss institutions, where the professional experience 
of the involved psychologists and neuropsychologists 
was comparable. Yet, the inclusion of patients remained 
a local decision.
• Although the brief NBD assessment battery meets satis-
fying psychometric criteria,32 it cannot be considered a 
full neuropsychological assessment and thus may have 
failed detecting other possible cognitive sequelae. Also, 
the distinct time points may have failed to detect neu-
ropsychological late effects, which may evolve at later 
points of time.
• Though comparison of cognitive outcome of pa-
tients receiving chemotherapy or radiotherapy was of 
prime interest, disparity for basic characteristics such 
as age or tumor site rendered statistical calculation 
impossible.
• Furthermore, the Beery-VMI is dependent on motor 
abilities and Gv score may therefore be influenced by 
these skills.
• The study also did not implement indirect assessment 
of QoL, socioeconomic status, or comparable ques-
tionnaires, while current recommendations agree on 
combining a brief assessment of direct and indirect 
measurements to analyze late effects in brain tumor 
trials,37–39 implemented as Core-Plus approach in QoS 
assessments in the European Ependymoma II trial.55
Conclusions
Patients with LGG of all intracranial sites without and with 
neurofibromatosis experience long-term cognitive impair-
ments in various domains. This even concerns patients fol-
lowing complete/subtotal resection of a cerebellar LGG and 
LGG patients without adjuvant treatment after biopsy or ra-
diological diagnosis; their deficits relate to visual processing, 
motor function, and processing speed. The degree of hydro-
cephalus at diagnosis does not seem to augment the extent 
of these deficits. Treatment allocation to either chemo- or ra-
diotherapy results in a comparable pattern of deficits.
Though impairment of cognitive abilities translates dif-
ferently in each patient, most patients show functional 
deficits in everyday life. Since adequate rehabilitation 
programs should be tailored to ameliorate these deficits, 
timely assessment of QoS status is crucial in clinical prac-
tice and mandatory as an endpoint in future LGG trials. 
Previous mono-institutional data were confirmed within 
our multi-institutional brain tumor network. Based on 
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indirect QoL assessments should be combined and evalu-
ated at distinct time points.
Supplementary Data
Supplementary data are available at Neuro-Oncology 
Advances online.
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